320 related articles for article (PubMed ID: 27528374)
21. The potential role of incretin therapy in the hospital setting.
Macdonald JJ; Neupane S; Gianchandani RY
Clin Diabetes Endocrinol; 2015; 1():4. PubMed ID: 28702223
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.
Neumiller JJ; Alicic RZ; Tuttle KR
J Am Soc Nephrol; 2017 Aug; 28(8):2263-2274. PubMed ID: 28465376
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.
Yugar LBT; Sedenho-Prado LG; da Silva Ferreira IMC; Silva CAM; Sposito AC; Cercato C
Diabetol Metab Syndr; 2024 Apr; 16(1):92. PubMed ID: 38659064
[TBL] [Abstract][Full Text] [Related]
24. Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Voroneanu L; Nistor I; Dumea R; Apetrii M; Covic A
J Diabetes Res; 2016; 2016():5147468. PubMed ID: 27340676
[TBL] [Abstract][Full Text] [Related]
25. Uncertainties around incretin-based therapies: A literature review.
Al Tulaihi B; Alhabib S
Saudi Pharm J; 2017 Jan; 25(1):1-7. PubMed ID: 28223856
[No Abstract] [Full Text] [Related]
26. The effect and safety of diacerein in patients with type 2 diabetes mellitus : a systematic review and meta-analysis.
Zhang Q; Zhou J; Wang Y; Chen D
Am J Clin Exp Immunol; 2017; 6(6):97-106. PubMed ID: 29348985
[TBL] [Abstract][Full Text] [Related]
27. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study.
Yi Y; Kwon EJ; Yun G; Park S; Jeong JC; Na KY; Chin HJ; Yoo S; Kim S; Oh TJ; Kim S; Jung CH; Lee H
Sci Rep; 2024 Jan; 14(1):2081. PubMed ID: 38267451
[TBL] [Abstract][Full Text] [Related]
28. Is eGFR Slope a Novel Predictor of Chronic Complications of Type 2 Diabetes Mellitus? A Systematic Review and Meta-Analysis.
Sartore G; Ragazzi E; Deppieri E; Lapolla A
J Diabetes Res; 2024; 2024():8859678. PubMed ID: 38268787
[TBL] [Abstract][Full Text] [Related]
29. Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece.
Migdalis IN; Papanas N; Ioannidis IM; Sotiropoulos AE; Raptis AE; Dimitriadis GD; On Behalf Of The Hellenic Diabetic Nephropathy Study Hdns
J Clin Med; 2021 May; 10(10):. PubMed ID: 34068380
[TBL] [Abstract][Full Text] [Related]
30. Targeting the incretin system in obesity and type 2 diabetes mellitus.
Ansari S; Khoo B; Tan T
Nat Rev Endocrinol; 2024 Apr; ():. PubMed ID: 38632474
[TBL] [Abstract][Full Text] [Related]
31. Advances in incretin-based therapeutics for obesity.
Rosenkilde MM
Nat Rev Endocrinol; 2024 Feb; 20(2):67-68. PubMed ID: 38062121
[No Abstract] [Full Text] [Related]
32. Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus.
Ansari S; Khoo B; Tan T
Nat Rev Endocrinol; 2024 May; ():. PubMed ID: 38714910
[No Abstract] [Full Text] [Related]
33. Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP into A Paradigm of Integrated Care.
Ostrominski JW; Lala A
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38917937
[No Abstract] [Full Text] [Related]
34. Investigations from the Belly of the Beast: N-Terminally Labeled Incretin Peptides That Are Both Potent Receptor Agonists and Stable to Protease Digestion.
Berger AA; Leppkes J; Koksch B
ACS Cent Sci; 2021 Mar; 7(3):400-402. PubMed ID: 33791422
[No Abstract] [Full Text] [Related]
35. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
36. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
Gæde P; Oellgaard J; Carstensen B; Rossing P; Lund-Andersen H; Parving HH; Pedersen O
Diabetologia; 2016 Nov; 59(11):2298-2307. PubMed ID: 27531506
[TBL] [Abstract][Full Text] [Related]
37. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
[TBL] [Abstract][Full Text] [Related]
38. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH
Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular safety trials of incretin-based drugs: What do they mean?
Yabe D; Seino Y
J Diabetes Investig; 2017 May; 8(3):272-276. PubMed ID: 27612317
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
